AU2023317392A1 - Cyclic peptide derivative, method for producing same, and composition - Google Patents

Cyclic peptide derivative, method for producing same, and composition Download PDF

Info

Publication number
AU2023317392A1
AU2023317392A1 AU2023317392A AU2023317392A AU2023317392A1 AU 2023317392 A1 AU2023317392 A1 AU 2023317392A1 AU 2023317392 A AU2023317392 A AU 2023317392A AU 2023317392 A AU2023317392 A AU 2023317392A AU 2023317392 A1 AU2023317392 A1 AU 2023317392A1
Authority
AU
Australia
Prior art keywords
group
hydrogen atom
compound
pharmaceutically acceptable
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023317392A
Other languages
English (en)
Other versions
AU2023317392A9 (en
Inventor
Yuma KARITA
Kohei Matsumoto
Takeshi SHOSU
Shichidai Tanabe
Kosuke YASUI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DKS Co Ltd
Original Assignee
DKS Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DKS Co Ltd filed Critical DKS Co Ltd
Publication of AU2023317392A1 publication Critical patent/AU2023317392A1/en
Publication of AU2023317392A9 publication Critical patent/AU2023317392A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2023317392A 2022-08-04 2023-08-04 Cyclic peptide derivative, method for producing same, and composition Pending AU2023317392A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2022-124810 2022-08-04
JP2022124810 2022-08-04
JP2022159060 2022-09-30
JP2022-159060 2022-09-30
PCT/JP2023/028632 WO2024029630A1 (ja) 2022-08-04 2023-08-04 環状ペプチド誘導体とその製造方法および組成物

Publications (2)

Publication Number Publication Date
AU2023317392A1 true AU2023317392A1 (en) 2025-02-20
AU2023317392A9 AU2023317392A9 (en) 2026-02-12

Family

ID=89849507

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023317392A Pending AU2023317392A1 (en) 2022-08-04 2023-08-04 Cyclic peptide derivative, method for producing same, and composition

Country Status (12)

Country Link
US (1) US20260035407A1 (https=)
EP (1) EP4567042A1 (https=)
JP (1) JPWO2024029630A1 (https=)
KR (1) KR20250044905A (https=)
CN (1) CN119731193A (https=)
AU (1) AU2023317392A1 (https=)
CO (1) CO2025001948A2 (https=)
IL (1) IL318676A (https=)
MX (1) MX2025001373A (https=)
PE (1) PE20250797A1 (https=)
TW (1) TW202423948A (https=)
WO (1) WO2024029630A1 (https=)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2016047638A1 (ja) * 2014-09-24 2016-03-31 国立大学法人岩手大学 環状ペプチド誘導体とその製造方法および組成物
JP7486328B2 (ja) * 2020-03-05 2024-05-17 株式会社バイオコクーン研究所 神経突起伸長促進剤、神経細胞の樹状突起発現促進剤、及び神経栄養因子様作用物質
JP7695662B2 (ja) * 2020-11-02 2025-06-19 公立大学法人大阪 環状ペプチド誘導体の製造方法及び環状ペプチド化合物の製造方法

Also Published As

Publication number Publication date
MX2025001373A (es) 2025-03-07
CN119731193A (zh) 2025-03-28
JPWO2024029630A1 (https=) 2024-02-08
IL318676A (en) 2025-03-01
KR20250044905A (ko) 2025-04-01
PE20250797A1 (es) 2025-03-14
AU2023317392A9 (en) 2026-02-12
US20260035407A1 (en) 2026-02-05
TW202423948A (zh) 2024-06-16
WO2024029630A1 (ja) 2024-02-08
CO2025001948A2 (es) 2025-03-06
EP4567042A1 (en) 2025-06-11

Similar Documents

Publication Publication Date Title
JP7659015B2 (ja) 免疫調節剤としての１，２，４－オキサジアゾールおよびチアジアゾール化合物
AU2010295461B2 (en) Process for preparing azabicyclic compounds
IL112606A (en) Mercaptoacetylamido 1, 3, 4, 5-tetrahydro-benzo ¬c¾ azepin -3- one disulfide derivatives process for their preparation and pharmaceutical compositions comprising them
JP3620644B2 (ja) アミノ酸誘導体およびそれらを有効成分として含有する薬剤
JPWO2000000470A1 (ja) アミノ酸誘導体およびそれらを有効成分として含有する薬剤
Dahiya Synthesis, characterization and antimicrobial studies on some newer imidazole analogs
JP6890865B1 (ja) 狂犬病治療のための環状アミド化合物およびその方法
FR2896247A1 (fr) Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
EP4613282A1 (en) Cyclic peptide derivative composition for treating or preventing central nervous system injury/disease
AU2023317392A1 (en) Cyclic peptide derivative, method for producing same, and composition
CN103405435B (zh) 克林沙星氨基衍生物及其可药用盐在制备抗结核药物中的应用
EP4595973A1 (en) Cyclic peptide derivative composition for treating or preventing eye disease
Asif et al. Synthesis of 2-amino-5-aryl-1, 3, 4-thiadiazolopeptides as potent antitubercular agents
FR2595704A1 (fr) Derives de la proline
IL320605A (en) Cyclic peptide derivative compound for the treatment or prevention of neuropathic pain and/or inflammatory pain
WO2025169980A1 (ja) テストステロンの産生／分泌を調節するための環状ペプチド誘導体組成物
JP2023084946A (ja) 生理活性を有する新規化合物
WO2025169981A1 (ja) 脳機能を改善するための環状ペプチド誘導体組成物
IL112605A (en) Enkephalinase and ace inhibiting disulfide derivatives of n-(tricyclic benzazepinyl) acetamide, their preparation and pharmaceutical composition containing them
JP2023084944A (ja) 生理活性を有する新規化合物
CN120271571A (zh) 一类谷胺酰胺环化酶抑制剂及其用途
JP2022091476A (ja) 新規含窒素三環性骨格化合物およびその使用
JPH0848679A (ja) ２−ピラノン誘導体及びそれを含有する免疫抑制剤
GB2395480A (en) Pyrrolo[1,2-a]pyridine & pyrrolo[1,2-a]azepine scaffolds useful for the synthesis of compounds with biological activity
JP2005068152A (ja) アミノ酸誘導体およびそれらを有効成分として含有する薬剤

Legal Events

Date Code Title Description
SREP Specification republished